Scott analyzes the sudden emergence of commercial trait-based embryo selection services, discussing both the scientific validity and ethical implications of selecting embryos for health outcomes, intelligence, and physical traits. Longer summary

Scott examines the recent development of commercial embryo selection services, particularly focusing on companies like Genomic Prediction, Orchid Health, Nucleus, and Herasight. He explains how the technology works, comparing different companies' claims and methodologies, and discusses both scientific challenges and ethical concerns. The post explores the potential benefits, like reduced disease risk and increased IQ, while acknowledging issues around cost, racial disparities, and social implications. A significant portion focuses on Herasight's critique of competitor Nucleus's scientific claims. The post concludes by placing this technology in the broader context of human enhancement and future technological developments. Shorter summary